Roche's rollout of thousands of Nvidia chips is the latest example of a pharmaceutical giant trying to use AI to discover and ...
Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its AI offerings and Nvidia partnership shortly after the ...
With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter, ...
StockStory.org on MSN
A look back at drug development inputs & services stocks’ Q4 earnings: Repligen (NASDAQ:RGEN) vs the rest of the pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...
Drug Development Insights: What New Industry Data Reveals for 2026, Upcoming Webinar Hosted by Xtalks In this free webinar, learn how today's industry trends and challenges are shaping drug ...
Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines. And ...
Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.
Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor ...
Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than ...
Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We'll be speaking ...
Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results